You searched for "gene therapy"

171 results found

What's trending Oct/Nov 2021

A round-up of the eye-related hot topics that have been trending on social media over the last few weeks. #cataracts #holography #simulation Cataracts are the major cause of blindness globally and innovating novel management strategies remains as important as ever...

ROP ocular outcomes after Bevacizumab treatment

The relationship between refractive outcomes and biometric parameters were evaluated following intravitreal Bevacizumab (IVB) monotherapy. Sixty-three infants were grouped into 1) infants treated with VB monotherapy for ROP (six with zone 1 and eight with posterior zone II retinopathy of...

CSD-OCT detection of minimally visible retinoblastoma

This paper reports minimally visible tumour recurrence that was detectable on spectral domain OCT (SD-OCT) in a two-month-old infant who had a diagnosis of bilateral familial retinoblastoma. The infant was treated with IVC for six cycles with vincristine, etoposide and...

SD-OCT detection of minimally visible retinoblastoma

This paper reports minimally visible tumour recurrence that was detectable on spectral domain OCT (SD-OCT) in a two-month old infant who had a diagnosis of bilateral familial retinoblastoma. The infant was treated with IVC for six cycles with vincristine, etoposide...

Bleomycin for conjunctival lymphangioma

This is a retrospective review of 16 eyes which underwent intralesional / sub-conjunctival injections of bleomycin sclerotherapy for conjunctival lymphatic malformations (lymphangiomas). The mean age was 18 (range three to 59 years). Four of the lesions were microcystic and 12...

Combined anti-VEGF and PDT for wet AMD

The authors report on a retrospective case series of combined anti-VEGF and photodynamic therapy (PDT) in the treatment of wet age-related macular degeneration (AMD) refractory to anti-VEGF monotherapy alone. The criteria for treatment failure of anti-VEGF monotherapy were persistent subretinal...

Outcomes of ‘treat and extend’ for neovascular AMD

The authors report on 24-month outcomes of anti-vascular endothelial growth factor (anti-VEGF) therapy using a ‘treat and extend’ regime for treatment-naïve neovascular age-related macular degeneration (nAMD). Data for this study was collected from the Fight Retinal Blindness observational registry based...

Management of diffuse OSSN with topical chemotherapy

Ocular surface squamous neoplasia (OSSN) can be localised to the conjunctiva or, less commonly, diffusely spread over the conjunctiva and cornea. Localised OSSN can be treated by surgical removal with adjuvant cryotherapy and chemotherapy with low rates of recurrence. Diffuse...

Outcomes of plaque radiotherapy for retinoblastoma

The study authors evaluate their experience of plaque radiotherapy for retinoblastoma (RB) in 41 eyes of 41 patients that failed intra-arterial chemotherapy (IAC). This was a retrospective review including 21 females and 20 males. Median age was 18 months and...

Medical treatment of orbital lymphatic malformations

This is a literature review of the use of Sirolimus, to treat orbital lymphatic malformations. Sirolimus is an immunosuppressant used in renal transplants, and acts by inhibiting mammalian target of rapamycin (mTOR), which in turn inhibits activation of T and...

Development of retinoblastoma care in Indonesia and the role of multidisciplinary team meetings

In the second article of a two-part series (See Part 1 here), the authors focus on the diagnosis and management of retinoblastoma in Indonesia. COVID-19 doesn’t get thanked for many things, but on 19 December 2020 as the world grew...

Long-term outcomes for hereditary retinoblastoma

Earlier diagnosis and more rigorous treatment regimens have contributed to better outcomes for patients with retinoblastoma. This study looked at 24 patients with hereditary bilateral retinoblastoma treated with systemic chemotherapy during a ten year period (2001-2011). The medical notes were...